Impact Factor
3.66
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.05
944 total citations
h5-index
35
h5 depth signal
Cited share
70.0%
168 of 240
Total citations
944
Citation footprint
Metric signal
3.69
External metric anchor
Self-citation
2.3%
22 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,058
Canada
68
China
63
Australia
30
Japan
18
Citing Fields of Research
Antibiotic & Antibacterial Agents
251
Cardiology
188
Pharmacology & Toxicology
131
Hematology
118
Respiratory Support
95
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,664
Articles tracked across the journal lifetime
Indexed publication set
240
168 cited publications
Last 12 months
129
10.8 publications/month
Open access share
25.6%
33 OA publications in the last year
Leading citing country
United States
1,058 citing publications
Leading citing field
Antibiotic & Antibacterial Agents
251 citing publications
Latest tracked publication
13 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1981-
v1n1, 1981-
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
Kidney Diseases
Pharmacology & Toxicology
Cardiology
Diabetes
Psychiatry
Issuing & Sponsoring Bodies
Contributor
American College of Clinical Pharmacy
Broad Categories
Drug Therapy
Antibiotic & Antibacterial Agents
Diabetes
Cardiology
Urology
Respiratory Support
HIV
MeSH Descriptors
Drug Therapy
Pharmacology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/phar.70184
Open DOI
Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses
Introduction: Non‐infectious uveitis (NIU) is a chronic immune‐mediated ocular inflammatory disease that may cause irreversible visual impairment. The comparative efficacy and safety of systemic immunomodulatory therapies, including conv...
02
DOI 10.1002/phar.70208
Open DOI
Cefepime‐Zidebactam: Leveraging β‐Lactam Enhancement Against Difficult‐to‐Treat and Metallo‐β‐Lactamase‐Producing Gram‐Negative Pathogens
Carbapenem resistance among Gram‐negative bacteria remains a serious public health threat, with metallo‐β‐lactamase (MBL)‐producing organisms increasing substantially in prevalence and few therapeutic options available to adequately addr...
03
DOI 10.1002/phar.70161
Open DOI
Issue Information
04
DOI 10.1002/phar.70206
Open DOI
Incretin Mimetics and Alcohol‐Related Outcomes: A Structured Narrative Review
Harmful alcohol use results in negative health outcomes for millions of patients each year, with limited effective treatment options available for those diagnosed with alcohol use disorder (AUD). Incretin mimetics, such as glucagon‐like‐...
05
DOI 10.1002/phar.70207
Open DOI
User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients With Kidney Impairment—A Case Series
Introduction: Evidence‐based dosing guidance for medications in critically ill patients with acute kidney injury (AKI) and receiving continuous kidney replacement therapy (CKRT) is limited. Freely available large language models (LLMs) c...
06
DOI 10.1002/phar.70204
Open DOI
Correction to “Women's Health in Oncology”
07
DOI 10.1002/phar.70203
Open DOI
Multisite Analysis of Vancomycin Concentration Predictions in a Bayesian Software in Adult and Pediatric Patients With and Without Acute Kidney Injury
Background: Bayesian software programs are recommended for area under the concentration‐time curve (AUC)‐guided vancomycin monitoring, but hesitancy remains for patients with acute kidney injury (AKI). Here, we assessed agreement between...
08
DOI 10.1002/phar.70200
Open DOI
Apixaban Use Before Kidney Transplantation: Is Reversal Necessary?
The use of apixaban prior to kidney transplantation is on the rise. However, optimal perioperative management remains uncertain, particularly regarding the need for preoperative reversal with four‐factor prothrombin complex concentrate (...
09
DOI 10.1002/phar.70202
Open DOI
Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer
Background: The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poor...
10
DOI 10.1002/phar.70199
Open DOI
Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury
Background: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TB...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Official journal of: American College of Clinical Pharmacy, <v. 12, no. 1->.
Vol. 1, no. 1 (JUL-AUG 1981)19900913 Notice published Printed on acid-free paper